Vivalyx secures 5.4 million euros in seed financing

New hope for organ transplants: Vivalyx receives fresh capital to improve donor organ quality
Aachen, April 30, 2024 - The Aachen-based organ vitality tech company Vivalyx GmbH has received an investment of 5.4 million euros in an oversubscribed seed financing round. The investment was led by TechVision Fonds (TVF) and Brightlands Venture Partners (BVP). The team, led by Dr. Andreas Schumacher and Dr. Benedict Doorschodt, is developing solutions to increase organ viability with the aim of increasing the number of organs available for life-saving transplants. The capital raised will be used to fund the necessary clinical trials to obtain regulatory approvals and to begin commercialization.
The financing round brings us a decisive step closer to bringing our products to the market.
Dr. Andreas Schumacher, CEO of Vivalyx.
Shortage of donor organs remains a critical unmet medical need
Patients and doctors are waiting for progress in the field of organ transplantation and the statistics back up the need for it. The average wait time for a donor kidney is up to eight years, and over one million patients worldwide are currently waiting for a donor organ.
This shortage of donor organs can be solved by perfusing organs at body temperature: a clinically proven method, but one that is hardly scalable due to its dependence on rare donor blood and high costs.
Vivalyx introduces a patented solution that overcomes this hurdle for the first time and makes perfusion at body temperature scalable. Their liquid product, Vivalyx Omnisol, outperforms the efficacy of the blood-based benchmark in preclinical studies, is fully synthetic - eliminating blood-related concerns - and significantly reduces costs. Vivalyx Omnisol not only works for body temperature perfusion, but is intended for all methods, cold and warm perfusion as well as static cold storage, with expected favorable clinical outcomes.
International investors and business angels invest in the founding team
We look forward to supporting the dedicated team and the outstanding technology together with this great consortium of investors in the coming years
Bernhard Kugel, Managing Director of TVF
Dr. Andreas Schumacher and Dr. Benedict Doorschodt founded Vivalyx 2022 together with co-founders Prof. Dr. René Tolba, Dr. Christian Bleilevens, Prof. Dr. Malte Brettel and Marius Rosenberg. The product idea is based on decades of research by Doorschodt, Tolba and Bleilevens. Overall, the team combines entrepreneurial experience with in-depth knowledge of organ transplants. In addition to the lead investors, the experienced founding team succeeded in attracting other industry experts such as Arve Capital, the US deeptech VC Goose Capital and other well-known business angels such as Springboard Health Angels, Andrej Henkler and Thomas Ebeling, former CEO of Novartis Pharma.

Newsletter
Startups, stories and stats from the German startup ecosystem straight to your inbox. Subscribe with 2 clicks. Noice.
LinkedIn ConnectTake care, give care
Did this news inform or entertain you? Then we would be happy if you tell your network about it.
Share on Linkedin Share on Facebook Share on XingRelated companies

FYI: English edition available
Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?
FYI: Deutsche Edition verfügbar
Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?